Hospital Pharmacy, University Hospital, LMU Munich, Munich, Germany.
Doctoral Program Clinical Pharmacy, University Hospital, LMU Munich, Munich, Germany.
J Clin Pharm Ther. 2021 Jun;46(3):838-845. doi: 10.1111/jcpt.13371. Epub 2021 Feb 20.
Renal impairment (RI) and renal drug-related problems (rDRP) often remain unrecognized in the community setting. A "renal pharmacist consultant service" (RPCS) at hospital admission can support patient safety by detecting rDRP. However, the efficient information sharing from pharmacists to physicians is still discussed. The aim of the study was to test the implementation of a RPCS and its effectiveness on prescription changes and to evaluate two ways of written information sharing with physicians.
Urological patients with eGFR of 15-59 ml/min and ≥1 drug were reviewed for manifest and potential rDRP at admission by a pharmacist. Written recommendations for dose or drug adaptation were forwarded to physicians comparing two routes: July-September 2017 paper form in handwritten chart; November 2017-January 2018 digital PDF document in the electronic patient information system and e-mail alert. Prescription changes regarding manifest rDRP were evaluated and compared with a previous retrospective study without RPCS.
The RPCS detected rDRP in 63 of 234 (26.9%) patients and prepared written recommendations (median 1 rDRP (1-5) per patient) concerning 110 of 538 (20.5%) drugs at admission. For manifest rDRP, acceptance rates of recommendations were 62.5% (paper) vs 42.9% (digital) (P = 0.16). Compared with the retrospective study without RPCS (prescription changes in 21/76 rDRP; 27.6%), correct prescribing concerning manifest rDRP significantly increased by 27.1%.
A RPCS identifies patients at risk for rDRP and significantly increases appropriate prescribing by physicians. In our hospital (no electronic order entry, electronic chart or ward pharmacists), consultations in paper form seem to be superior to a digital PDF document.
肾功能损害(RI)和与肾脏相关的药物问题(rDRP)在社区环境中经常未被发现。入院时的“肾脏药剂师顾问服务”(RPCS)可以通过检测 rDRP 来支持患者安全。然而,药剂师与医生之间的有效信息共享仍在讨论中。本研究的目的是测试 RPCS 的实施及其对处方变更的有效性,并评估与医生分享书面信息的两种方式。
对 eGFR 为 15-59 ml/min 且至少有 1 种药物的泌尿科患者进行入院时显性和潜在 rDRP 的审查,由药剂师进行审查。针对剂量或药物适应性的书面建议通过两种途径转发给医生:2017 年 7 月至 9 月手写图表中的纸质表格;2017 年 11 月至 2018 年 1 月电子患者信息系统中的数字 PDF 文档和电子邮件提醒。评估显性 rDRP 的处方变更,并与没有 RPCS 的先前回顾性研究进行比较。
RPCS 在 234 名患者中的 63 名(26.9%)患者中发现了 rDRP,并在入院时为 538 种药物中的 110 种(20.5%)准备了书面建议(中位数为 1 个 rDRP(1-5)/患者)。对于显性 rDRP,建议的接受率为 62.5%(纸质)与 42.9%(数字)(P=0.16)。与没有 RPCS 的回顾性研究(21/76 rDRP 中有 21 种处方变更;27.6%)相比,显性 rDRP 的正确处方显著增加了 27.1%。
RPCS 可识别出有 rDRP 风险的患者,并显著增加医生的适当处方。在我们的医院(没有电子医嘱输入、电子病历或病房药剂师)中,纸质形式的咨询似乎优于数字 PDF 文档。